Ticker Details
Atara Biotherapeutics, Inc. Atara Biotherapeutics Inc is engaged in the development of pharmaceutical products. The company's focus lies on developing therapies addressing serious-life threatening diseases in the United States.
IPO Date:	October 16, 2014
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$39.5M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.62 | 3.90%
Avg Daily Range (30 D):	$0.25 | 4.71%
Avg Daily Range (90 D):	$0.44 | 4.90%

Institutional Daily Volume
Avg Daily Volume:	.27M
Avg Daily Volume (30 D):	.29M
Avg Daily Volume (90 D):	.29M

Trade Size
Avg Trade Size (Sh.):	58
Avg Trade Size (Sh.) (30 D):	80
Avg Trade Size (Sh.) (90 D):	98

Institutional Trades
Total Institutional Trades:	2,721
Avg Institutional Trade:	$2.22M
Avg Institutional Trade (30 D):	$.52M
Avg Institutional Trade (90 D):	$.52M
Avg Institutional Trade Volume:	.01M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2M
Avg Closing Trade (30 D):	$4.55M
Avg Closing Trade (90 D):	$4.55M
Avg Closing Volume:	6.14K

News

Apr 9, 2026 @ 6:58 PM ROSEN, A LEADING NATIONAL FIRM, Encourages Atara B... Source: Rosen Law Firm

Apr 7, 2026 @ 10:00 PM ATRA INVESTOR REMINDER: Atara Biotherapeutics, Inc... Source: Kirby Mcinerney Llp

Apr 6, 2026 @ 8:00 PM Shareholders that lost money on Atara Biotherapeut... Source: Levi & Korsinsky, Llp

Apr 6, 2026 @ 4:00 PM Bronstein, Gewirtz & Grossman LLC Urges Atara Biot... Source: Bronstein, Gewirtz & Grossman Llc

Apr 4, 2026 @ 1:27 AM ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Ata... Source: Rosen Law Firm

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$2.61	$-.35	$2.61
Diluted EPS	$2.57	$-.36	$2.57
Revenue	$120.77M	$1.6M	$120.77M
Gross Profit
Net Income / Loss	$32.69M	$-3.41M	$32.69M
Operating Income / Loss	$35.86M	$-2.56M	$35.86M
Cost of Revenue
Net Cash Flow	$-16.69M	$2.74M	$-16.69M
PE Ratio	1.81

Splits
Jun 20, 2024	1:25